Harrow (NASDAQ:HROW) versus Royalty Pharma (NASDAQ:RPRX) Financial Survey

Harrow (NASDAQ:HROW) and Royalty Pharma (NASDAQ:RPRX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Profitability

This table compares Harrow and Royalty Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Harrow	-13.51%	-38.00%	-3.37%
Royalty Pharma	32.14%	30.01%	14.91%

Earnings & Valuation

This table compares Harrow and Royalty Pharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30 million	3.86	-$5.14 million	($1.00)	-28.07
Royalty Pharma	$2.38 billion	15.05	$770.95 million	$1.45	42.93

Royalty Pharma has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Harrow has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Harrow and Royalty Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1	2	7	0	2.60
Royalty Pharma	0	0	8	0	3.00

Harrow presently has a consensus price target of $66.17, indicating a potential upside of 135.72%. Royalty Pharma has a consensus price target of $61.57, indicating a potential downside of 1.09%. Given Harrow’s higher possible upside, research analysts plainly believe Harrow is more favorable than Royalty Pharma.

Insider and Institutional Ownership

72.8% of Harrow shares are owned by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Royalty Pharma beats Harrow on 11 of the 13 factors compared between the two stocks.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.